Skip to main content
. Author manuscript; available in PMC: 2007 Feb 26.
Published in final edited form as: J Gene Med. 2006 May;8(5):603–615. doi: 10.1002/jgm.877

Figure 4.

Figure 4

NV1066 prolongs survival in murine malignant pleural mesothelioma model. MPM was established in mice after intrapleural instillation of MSTO-211H cells (1 × 107). Mice were treated with either PBS or NV1066 (1 × 107 pfu) injected intrapleurally. NV1066 significantly improved the median survival in the early treatment (day 5) group (A), (p < 0.001); late treatment (day 11) group with one dose (B), (p = 0.002) or three doses (B), (p = 0.002); and with systemic treatment with three doses (C), (p < 0.001). Each dose was administered as 1 × 107 pfu either intrapleurally or systemically by tail vein injection. pfu = plaque forming unit.